Thymoma-associated myasthenia gravis (TAMG) accounts for 15–20% of all myasthenia gravis (MG) cases and is typically associated with autoantibodies targeting the acetylcholine receptor (AChR-Abs) located at the postsynaptic membrane of the neuromuscular junction (1, 2). The gene discussed is DDX41; the disease is myasthenia gravis.